Analysis of the mechanisms of acquired resistance to molecular-targeted therapy in lung cancer using liquid biopsy of circulating nucleotide acids and circulating tumor cells

Analysis of the mechanisms of acquired resistance to molecular-targeted therapy in lung cancer using liquid biopsy of circulating nucleotide acids and circulating tumor cells - Analysis of the mechanisms of acquired resistance to molecular-targeted therapy in lung cancer using liquid biopsy of circulating nucleotide acids and circulating tumor cells

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031472

Enrollment

Registered

2018-03-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically proven lung cancer with EGFR mutation A re-biopsy was planned within 2 weeks after progression under EGFR-TKI treatment written informed consent

Exclusion criteria

Exclusion criteria: inappropriate participation judged by the attending physician

Design outcomes

Primary

Measure	Time frame
gene analysis	—

Countries

Japan

Contacts

Public ContactTetsunari Hase

Nagoya University Hospital Department of Respiratory Medicine

thase@med.nagoya-u.ac.jp052-741-2111

Outcome results